20
Participants
Start Date
June 23, 2014
Primary Completion Date
October 23, 2015
Study Completion Date
April 5, 2016
Refametinib (BAY86-9766)
"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
Regorafenib (Stivarga, BAY73-4506)
"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
Chapel Hill
Detroit
St Louis
Houston
New Haven
Lead Sponsor
Bayer
INDUSTRY